NEW YORK (GenomeWeb News) – ARUP Laboratories will begin offering Decode Genetics' prostate cancer test in the fall under a deal announced today.
ARUP will offer Decode's ProstateCancer test to academic medical centers, public and private healthcare providers, and major hospitals in the US as part of its portfolio of tests. The test will be ordered through ARUP, which will handle patient samples and results. Decode will analyze the samples in its CAP and CLIA-certified laboratory.
The two companies did not reveal the terms of the agreement.
The ProstateCancer test measures 25 common SNPs associated with prostate cancer risk. In a statement, the companies said that the test can identify about 15 percent of men who are at double the average risk of prostate cancer and 5 percent of men who are at triple the average risk.
The test is meant as a complement to standard clinical risk screening methods, such as PSA.
ARUP is a reference laboratory owned by the University of Utah.